Pancreatic Cancer Research

ResearcherKagawa UniversityActive in the last 2 years

Keiichi Okano

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9559-6182; OpenAlex author ID A5025984729, A5048350662, A5052488745. Sources: OpenAlex.

Their work

Papers
34 (first author 8, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
101
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 3 papers · 2022: 5 papers · 2023: 3 papers · 2024: 6 papers · 2025: 3 papers · 2026: 4 papers

Papers 34

  1. Preoperative Prediction of Pathologic Response After Neoadjuvant Chemoradiotherapy for Pancreatic Ductal Adenocarcinoma: A Metabolic Response-Based Predictive … Last author DOI 10.1002/jso.70360↗
  2. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  3. A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and Borderline Resectabl… Last author DOI 10.1245/s10434-025-18714-7↗
  4. ASO Visual Abstract: A Phase II Study of Short-Course Neoadjuvant Chemoradiotherapy with Gemcitabine, S-1, and Hypofractionated Radiotherapy for Resectable and… Last author DOI 10.1245/s10434-025-18894-2↗
  5. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  6. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  7. Predicting pathological response to neoadjuvant chemoradiotherapy in resectable and borderline resectable pancreatic ductal adenocarcinoma: a comparative study… Co-author DOI 10.1186/s13550-025-01342-3↗
  8. Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by c… Last author DOI 10.1002/jhbp.1424↗
  9. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant ch… Last author DOI 10.1016/j.pan.2024.02.007↗
  10. Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emission tomography in patients with resectabl… Last author DOI 10.1016/j.pan.2024.08.010↗
  11. Serum Carbohydrate Antigen 19-9 and Metabolite Hypotaurine Are Predictive Markers for Early Recurrence of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002304↗
  12. Prognostic Significance of 18F-FDG PET/CT and Tumor Metabolic Changes in Patients With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/anticanres.17151↗
  13. Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable … Last author DOI 10.3390/jcm13051216↗
  14. P53 immunolabeling in EUS-FNA biopsy can predict low resection rate and early recurrence in resectable or borderline resectable pancreatic cancer treated with … First author DOI 10.1002/jhbp.1286↗
  15. Efficacy of neoadjuvant chemoradiotherapy followed by pancreatic resection for older patients with resectable and borderline resectable pancreatic ductal adeno… Last author DOI 10.1016/j.hpb.2022.10.004↗
  16. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  17. Prediction of local tumor control and recurrence-free survival in patients with pancreatic cancer undergoing curative resection after neoadjuvant chemoradiothe… First author DOI 10.1002/jso.26854↗
  18. Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer. First author DOI 10.1093/jjco/hyac074↗
  19. Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002011↗
  20. Role of Short-Term Neoadjuvant Chemoradiotherapy for Potentially Resectable Pancreatic Cancer. Co-author DOI 10.1177/0003134821998671↗
  21. Effect of Aspirin on G0/G1 Cell Cycle Arrest and microRNA Signatures in Pancreatic Adenocarcinoma Cells. Co-author DOI 10.21873/anticanres.15900↗
  22. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.09.006↗
  23. Adequate tissue sampling for the assessment of pathological tumor regression in pancreatic cancer. Co-author DOI 10.1038/s41598-021-86152-y↗
  24. Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrosp… Co-author DOI 10.1159/000517244↗
  25. Changes and prognostic impact of inflammatory nutritional factors during neoadjuvant chemoradiotherapy for patients with resectable and borderline resectable p… First author DOI 10.1186/s12876-020-01566-8↗
  26. Is surgery after neoadjuvant chemoradiotherapy feasible for elderly patients with resectable or borderline resectable pancreatic ductal adenocarcinoma? First author DOI 10.21203/rs.2.21112/v1↗
  27. The predictors and patterns of the early recurrence of pancreatic ductal adenocarcinoma after pancreatectomy: the influence of pre- and post- operative adjuvan… First author DOI 10.1186/s12893-019-0644-z↗
  28. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Co-author DOI 10.1093/jjco/hyy033↗
  29. MicroRNA profiles during galectin-9-induced apoptosis of pancreatic cancer cells. Co-author DOI 10.3892/ol.2017.7316↗
  30. A Prospective Phase II Trial of Neoadjuvant S-1 with Concurrent Hypofractionated Radiotherapy in Patients with Resectable and Borderline Resectable Pancreatic … Co-author DOI 10.1245/s10434-017-5921-4↗
  31. [PET imaging in the diagnosis of pancreatic cancer]. Co-author PMID 25856989↗
  32. Strategies for early detection of resectable pancreatic cancer. Co-author DOI 10.3748/wjg.v20.i32.11230↗
  33. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic… First author DOI 10.1097/sla.0b013e3182827a65↗
  34. 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer. Co-author DOI 10.3748/wjg.v17.i2.231↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Minoru Oshima · 24 shared papers, 2013–2026 · strength 3.74
  2. Hironobu Suto · 20 shared papers, 2017–2026 · strength 3.32
  3. Yasuyuki Suzuki · 16 shared papers, 2013–2023 · strength 1.82
  4. Toru Shibata · 11 shared papers, 2017–2026 · strength 1.74
  5. Tsutomu Masaki · 14 shared papers, 2017–2024 · strength 1.72
  6. Mina Nagao · 8 shared papers, 2018–2024 · strength 1.32
  7. Shigeo Takahashi · 8 shared papers, 2017–2024 · strength 1.10
  8. Akihito Tsuji · 5 shared papers, 2018–2026 · strength 0.90
  9. Ayaka Shimomura · 4 shared papers, 2021–2024 · strength 0.58
  10. Tsutomu Fujii · 3 shared papers, 2023–2026 · strength 0.48
  11. Takashi Norikane · 2 shared papers, 2024–2025 · strength 0.42
  12. Satoshi Hirano · 2 shared papers, 2025–2026 · strength 0.35
  13. Masayuki Ohtsuka · 2 shared papers, 2025–2026 · strength 0.35
  14. Yoo‐Seok Yoon · 2 shared papers, 2023–2026 · strength 0.32
  15. Yukiko Wada · 2 shared papers, 2022–2024 · strength 0.29
  16. Sohei Satoi · 2 shared papers, 2023–2025 · strength 0.28
  17. Yoshifumi Takeyama · 2 shared papers, 2023–2025 · strength 0.28
  18. Yuichi Nagakawa · 2 shared papers, 2023–2025 · strength 0.28
  19. Y Nishiyama · 1 shared paper, 2025 · strength 0.24
  20. Keiko Yamakawa · 2 shared papers, 2021 · strength 0.22
  21. Yoko Matsuda · 2 shared papers, 2021 · strength 0.22
  22. Juanjuan Ye · 2 shared papers, 2021 · strength 0.22
  23. Motohiro Kojima · 2 shared papers, 2021 · strength 0.22
  24. Masanao Yokohira · 2 shared papers, 2021 · strength 0.22
  25. Isamu Makino · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.